| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9180259 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9533102 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US9629959 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US11446441 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US10478560 | ANTARES PHARMA INC | Prefilled syringe injector |
Jan, 2026
(2 years from now) | |
| US8562564 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Jan, 2026
(2 years from now) | |
| US8021335 | ANTARES PHARMA INC | Prefilled syringe jet injector |
Oct, 2026
(3 years from now) | |
| US11497753 | ANTARES PHARMA INC | Hazardous agent injection system |
Mar, 2030
(6 years from now) | |
| US10279131 | ANTARES PHARMA INC | Injection device with cammed RAM assembly |
Jul, 2031
(7 years from now) | |
| US11446440 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US10905827 | ANTARES PHARMA INC | Injection device with cammed ram assembly |
Aug, 2031
(7 years from now) | |
| US10357609 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Aug, 2031
(7 years from now) | |
| US10821072 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Jun, 2033
(9 years from now) | |
| US10881798 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2034
(10 years from now) | |
| US11160751 | ANTARES PHARMA INC | Hematocrit modulation through needle assisted jet injection of testosterone |
Oct, 2034
(11 years from now) | |
| US10238662 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Feb, 2035
(11 years from now) | |
| US10912782 | ANTARES PHARMA INC | Needle assisted injection administration of testosterone compositions |
Feb, 2035
(11 years from now) | |
| US11191908 | ANTARES PHARMA INC | Syringe shock absorber for use in an injection device |
Oct, 2035
(12 years from now) | |
| US9744302 | ANTARES PHARMA INC | Needle assisted jet injection device having reduced trigger force |
Nov, 2035
(12 years from now) | |
| US9950125 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Sep, 2036
(12 years from now) | |
| US10646495 | ANTARES PHARMA INC | Testosterone ester triglyceride formulations |
Aug, 2038
(14 years from now) | |
Xyosted (Autoinjector) is owned by Antares Pharma Inc.
Xyosted (Autoinjector) contains Testosterone Enanthate.
Xyosted (Autoinjector) has a total of 21 drug patents out of which 0 drug patents have expired.
Xyosted (Autoinjector) was authorised for market use on 28 September, 2018.
Xyosted (Autoinjector) is available in solution;subcutaneous dosage forms.
Xyosted (Autoinjector) can be used as method of administering testosterone enanthate subcutaneously.
The generics of Xyosted (Autoinjector) are possible to be released after 30 August, 2038.
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
XYOSTED (AUTOINJECTOR) family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic